Champions Oncology financials
$4.79−2.84%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Apr 30 | FY25 Apr 30 | FY24 Apr 30 | FY23 Apr 30 | FY22 Apr 30 | FY21 Apr 30 | FY20 Apr 30 | FY19 Apr 30 | FY18 Apr 30 | FY17 Apr 30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59.4M | $56.9M | $50.2M | $53.9M | $49.1M | $41.0M | $32.1M | $27.1M | $20.2M | $15.4M |
| Gross profit | $28.5M | $28.6M | $20.8M | $24.3M | $25.5M | $19.6M | $15.1M | $12.8M | $9.7M | $5.7M |
| Gross margin | 48.0% | 50.1% | 41.4% | 45.2% | 51.9% | 47.7% | 47.1% | 47.3% | 47.9% | 37.0% |
| Operating income | -$1.0M | $4.8M | -$7.4M | -$5.3M | $607.0K | $366.0K | -$1.9M | $270.0K | -$1.4M | -$6.8M |
| Net income | -$1.2M | $4.7M | -$7.3M | -$5.3M | $548.0K | $362.0K | -$2.1M | $128.0K | -$1.5M | -$6.9M |
| Net margin | −2.0% | 8.3% | −14.5% | −9.9% | 1.1% | 0.9% | −6.5% | 0.5% | −7.3% | −44.7% |
| Diluted EPS | $-0.08 | $0.33 | $-0.54 | $-0.39 | $0.04 | $0.02 | $-0.18 | $0.01 | $-0.13 | $-0.64 |
| EBITDA | $348.0K | $6.5M | -$5.1M | -$2.2M | $2.2M | $1.6M | -$761.0K | $876.0K | -$994.0K | -$6.6M |
| Operating cash flow | -$4.5M | $7.4M | -$6.1M | $4.0M | $6.5M | -$1.7M | $2.9M | $1.9M | -$1.2M | -$2.8M |
| Free cash flow | -$5.0M | $7.0M | -$7.0M | $1.1M | $4.1M | -$5.0M | $685.0K | $1.0M | -$2.5M | -$3.6M |
| Diluted shares | 13.8M | 14.3M | 13.5M | 13.5M | 14.2M | 14.6M | 11.8M | 14.1M | 11.0M | 10.7M |
Balance sheet
| Period end | Apr 30 | Apr 30 | Apr 30 | Apr 30 | Apr 30 | Apr 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.9M | $9.8M | $2.6M | $10.1M | $9.0M | $4.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $72.0K | $0.00 |
| Total assets | $27.0M | $32.3M | $26.1M | $34.3M | $35.4M | $27.6M |
| Total liabilities | $22.9M | $28.6M | $28.0M | $29.7M | $26.3M | $20.2M |
| Shareholders' equity | $4.1M | $3.8M | -$1.9M | $4.6M | $9.1M | $7.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology